Peak expiratory flow increases were greater with benralizumab than placebo in patients with severe eosinophilic asthma.
Patients with both asthma and allergies had a significant increase in the number of prescriptions dispensed for controller medications.
Results found that infants with an unknown epilepsy etiology, a normal MRI, an EEG displaying hypsarrhythmia, or those already receiving an AED were more likely to be administered ACTH.
Children with asthma who experience chronic oral glucocorticoid exposure may have significant morbidities, including adrenal suppression, recurrent pneumonia, and behavioral problems.
Omalizumab therapy was associated with reduced exacerbation and hospitalization rates in US clinics, according to findings from the prospective multicenter observational registry PROSPERO study
Reslizumab reduced the risk for exacerbations and improved lung function when compared to placebo, in patients with severe eosinophilic asthma.
Oral contraceptive use in women of reproductive age may increase the risk for lifetime asthma.
Treatment with single-agent carfilzomib achieved durable responses in patients with relapsed/refractory multiple myeloma whose disease had relapsed after they received all available therapies (including bortezomib and immunomodulatory agents), suggesting that this agent has the potential to offer substantial clinical benefit. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.